Lite Strategy, Inc. Changes Certifying Accountant
Ticker: LITS · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Lite Strategy, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00000002 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, corporate-action
TL;DR
Lite Strategy (LIT) swapped auditors, watch for financial statement implications.
AI Summary
Lite Strategy, Inc. (formerly MEI Pharma, Inc.) filed an 8-K on December 5, 2025, reporting a change in its certifying accountant. The company, located at 9920 Pacific Heights Blvd., Suite 150, San Diego, CA 92121, is in the Pharmaceutical Preparations industry.
Why It Matters
A change in a company's auditor can signal potential issues with financial reporting or a desire for a fresh perspective on financial statements.
Risk Assessment
Risk Level: medium — Changes in certifying accountants can sometimes precede or coincide with financial irregularities or restatements.
Key Players & Entities
- Lite Strategy, Inc. (company) — Registrant
- MEI Pharma, Inc. (company) — Former company name
- MARSHALL EDWARDS INC (company) — Former company name
- 2834 (industry_code) — Standard Industrial Classification
- 9920 PACIFIC HEIGHTS BLVD (address) — Principal Executive Offices
- SAN DIEGO (location) — City of Principal Executive Offices
- CA (location) — State of Principal Executive Offices
- 92121 (zip_code) — Zip Code of Principal Executive Offices
- 858-369-7100 (phone_number) — Business Phone Number
- December 02, 2025 (date) — Date of earliest event reported
FAQ
What is the primary reason for Lite Strategy, Inc. changing its certifying accountant?
The filing does not explicitly state the reason for the change in certifying accountant, only that it is a change.
When was the change in certifying accountant reported?
The change was reported on a Form 8-K filed on December 5, 2025, with the earliest event date being December 2, 2025.
What was Lite Strategy, Inc. previously known as?
Lite Strategy, Inc. was formerly known as MEI Pharma, Inc. and before that, MARSHALL EDWARDS INC.
What is Lite Strategy, Inc.'s Standard Industrial Classification code?
Lite Strategy, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Lite Strategy, Inc. headquartered?
Lite Strategy, Inc.'s principal executive offices are located at 9920 Pacific Heights Blvd., Suite 150, San Diego, California, 92121.
Filing Stats: 841 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2025-12-05 16:00:24
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value LITS The Nasdaq Stock Mar
Filing Documents
- lits-20251202.htm (8-K) — 49KB
- lits-ex16_1.htm (EX-16.1) — 4KB
- 0001193125-25-309593.txt ( ) — 159KB
- lits-20251202.xsd (EX-101.SCH) — 24KB
- lits-20251202_htm.xml (XML) — 5KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant. The Audit Committee (the "Committee") of the Board of Directors (the "Board") of Lite Strategy, Inc. (the "Company") undertook a selection process to determine the Company's independent registered public accounting firm for the current fiscal year ending June 30, 2026. On December 2, 2025, the Committee approved the engagement of CBIZ CPAs P.C. ("CBIZ CPAs") as its independent registered public accounting firm for the fiscal year ending June 30, 2026. At the same time, the Committee dismissed Deloitte & Touche LLP ("Deloitte") as independent registered public accounting firm of the Company effective December 2, 2025. This change was not a result of any disagreement between the Company and Deloitte. The audit reports of Deloitte on the Company's financial statements for the years ended June 30, 2025 and 2024 did not contain an adverse opinion or disclaimer of opinion, and such reports were not qualified or modified as to uncertainty, audit scope, or accounting principle. During the fiscal years ended June 30, 2025 and 2024, and the subsequent interim period through September 30, 2025, there were: (i) no "disagreements" (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Deloitte on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Deloitte's satisfaction, would have caused Deloitte to make reference to them in its reports; and (ii) no "reportable events" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K). The Company provided Deloitte with a copy of the disclosures the Company is making in this Current Report on Form 8-K and requested that Deloitte furnish a letter to the Company addressed to the U.S. Securities and Exchange Commission ("SEC") stating whether it agrees with the statements made herein. A copy of Deloitte's
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Title 16.1 Letter from Deloitte 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LITE STRATEGY, INC. Date: December 5, 2025 By: /s/ Justin J. File Justin J. File Chief Executive Officer, Chief Financial Officer and Secretary